Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Altimmune Announces Pemvidutide As The Only Drug Granted Fast Track Designation In Alcohol Use Disorder With Phase 2 RECLAIM Study Ongoing

Author: Benzinga Newsdesk | August 19, 2025 07:33am
  • Pemvidutide is the only drug currently granted Fast Track Designation in AUD
  • RECLAIM, a Phase 2 trial of pemvidutide in AUD, is currently enrolling

Posted In: ALT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist